Oculis Holding AG: First Patient Treated in PIONEER-1 Registrational Trial of Privosegtor for Optic Neuritis

The PIONEER program marks a key step toward potential first-in-class neuroprotection for optic neuritis and other neurological diseases, supported by positive Acuity Phase 2 data, FDA Breakthrough...